AlphaQuest’s Trevi Therapeutics TRVI Stock Holding History

AlphaQuest’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,988	Closed	-$100K	–	1931
2025 Q4	$100K	Sell	7,988 -709	-8%	-$8.19K	0.01%	1745
2025 Q3	$79.6K	Buy	+8,697	New	+$65.2K	0.01%	1806

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

AlphaQuest's TRVI Position: Q1 2026 in Review

AlphaQuest sold out of Trevi Therapeutics (TRVI) in Q1 2026, closing a stake of 7,988 shares — an estimated $100K sold.

AlphaQuest first reported a position in TRVI in Q3 2025 and held it in 2 quarters. The position peaked at $100K in Q4 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

AlphaQuest reported no remaining Trevi Therapeutics position as of Q1 2026 after selling out during the quarter.
AlphaQuest sold 7,988 Trevi Therapeutics shares in Q1 2026, an estimated $100K.
AlphaQuest first reported a position in Trevi Therapeutics in Q3 2025 and held it in 2 quarters.
AlphaQuest's Trevi Therapeutics position peaked at $100K in Q4 2025.
198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.